Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
about
Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseasesEmerging therapies for severe asthmaTherapeutic targets in the ASK1-dependent stress signaling pathwaysDelivering regenerative cues to the heart: cardiac drug delivery by microspheres and peptide nanofibers.Inhibition of JNK and p38 MAPK phosphorylation by 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester and 4-phenyl-butenoic acid decreases substance P-induced TNF-α upregulation in macrophagesInhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production.Back to the future: oral targeted therapy for RA and other autoimmune diseases.A novel chromone derivative with anti-inflammatory property via inhibition of ROS-dependent activation of TRAF6-ASK1-p38 pathwaySelective JAK inhibitors in development for rheumatoid arthritis.A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.Intraplantar-injected ceramide in rats induces hyperalgesia through an NF-κB- and p38 kinase-dependent cyclooxygenase 2/prostaglandin E2 pathway.Lack of the T cell-specific alternative p38 activation pathway reduces autoimmunity and inflammationAnti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor.A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease.New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma.MAPK-activated protein kinase 2 contributes to Clostridium difficile-associated inflammationStructural basis for the regulation of the mitogen-activated protein (MAP) kinase p38α by the dual specificity phosphatase 16 MAP kinase binding domain in solutionEliminative signaling by Janus kinases: role in the downregulation of associated receptors.Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk.An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola.Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity.Nanotherapeutic approaches for the treatment of rheumatoid arthritis.Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.Microcrystals as DAMPs and their role in joint inflammation.Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.The miR-17 ∼ 92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis.Cell-signaling therapy in rheumatoid arthritis.Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.Methotrexate: a gold standard for treatment of rheumatoid arthritis.Novel approaches to the management of noneosinophilic asthma.Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.Hydroxysafflor yellow A inhibits IL-1β-induced release of IL-6, IL-8, and MMP-1 via suppression of ERK, NF-κB and AP-1 signaling in SW982 human synovial cells.Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia.The p38 mitogen-activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis.Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell propertiesA Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [14 C]Seletalisib (UCB5857) in Healthy Subjects.OA10 is a novel p38alpha mitogen-activated protein kinase inhibitor that suppresses osteoclast differentiation and bone resorption.Inhibition of spleen tyrosine kinase as treatment of postoperative ileus.Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibition.
P2860
Q26823714-AEF36221-36FF-4053-A77C-CC71BC18C18FQ26861260-116952C8-2E8F-4F19-A179-E13C76DDEBFCQ26999030-37599A65-BBF0-492A-AF0C-034E283356C8Q30473970-D89E776C-A882-4586-B912-C2FBF45613D8Q33959580-BB9AFF7A-E266-4652-AB04-D0164D3BDAC9Q34007875-ABB0EBB1-8917-45F0-BA31-B4D4C45B9D35Q34213332-E12EA2C5-F3D1-4A1F-ABE8-4ABE76D34395Q34312376-48A28B61-64D2-4A55-93DB-9EC066328678Q34419615-56D46B24-B77C-4A41-BB79-34BBDEC968DCQ35093044-A1BCB0D3-68CC-4C71-A0F1-3FADBBBCB6FAQ35105360-5FB36AF8-92E0-4B77-904B-31222EA595FBQ35230204-1A5C6618-D027-4354-9D21-88873C0041D4Q35600218-F9A0D666-7328-4816-AE0C-13B180FCE190Q36094049-088DEA86-0742-4596-AF3F-A7C4C819C2E1Q36252920-14315CBC-2A80-487E-8495-212663E46F1CQ36646782-EDCD8550-C1F8-4222-9C40-9F3C889DDCF8Q37201320-7E85445E-5A15-43AA-8A5B-6D92542E34A9Q37377109-7A0097C4-DC06-40BE-BAA0-0D1CCB1FB954Q37808572-489A2689-1D4E-4C30-9FA4-F2CF535D83EAQ37809089-E237EC61-107D-472C-929E-33E78197CC52Q37813704-E4F58AEC-406A-4E74-94C1-A3BA57035733Q37916426-5241B759-992C-4BA1-AB30-C3C46F8B45F3Q37960141-D1203476-E00D-4E76-8A2F-B8BCE4A2A42AQ37983851-029A92CA-DD34-4451-820E-784CB7941D0BQ38042734-424F9EA1-3A67-4252-A25D-7AC0E8B6EA5AQ38091666-007B9998-5DDD-4BB9-9F40-6789C376E038Q38129724-E780015F-844D-4AB4-9BFB-5AD20A90ACD1Q38251801-D9736961-DFCF-40C3-8BAF-983EE493DC90Q38260785-7A92F67E-3E68-40CE-9827-8E405C38E761Q38756064-9E1EA66C-FC3E-4F84-8653-88DFE0967460Q38826405-C2983CC6-3820-4DF6-A211-36C840C12E54Q39314451-5ED80F84-7506-4D91-91B2-707EB2B9DDD7Q40321458-994FBCE3-7BE3-49F6-B670-06A596C1148FQ40815617-2B1E3323-4135-4EE1-BAE7-11BB455D1322Q41948703-7B499AA6-C9AC-40BA-A07D-7B49E5767C7DQ42078200-BA18D0DD-4A92-451E-9044-BBD3C51172B1Q50560944-13474E63-1F2E-427F-B224-05CA93B4B199Q50701558-EAD200CD-E70E-4405-B161-609830D7A8AAQ54465425-85D14238-E0C8-4442-A5BA-0FBA5695BDF4Q54496230-FE58B753-3AB8-4AF3-9B35-8C03FADD0B4B
P2860
Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
@en
Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
@nl
type
label
Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
@en
Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
@nl
prefLabel
Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
@en
Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
@nl
P1476
Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
@en
P2093
Roy Fleischmann
Stanley Cohen
P304
P356
10.1097/BOR.0B013E3283378E6F
P577
2010-05-01T00:00:00Z